Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression
Mertens, L. J., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D. J., & Carhart-Harris, R. L. | Journal of Psychopharmacology | 16 January 2020
Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers.
Murphy-Beiner, A., & Soar, K. | Psychopharmacology | 11 January 2020
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. | Neuropharmacology | 7 January 2020
Esketamine is approved in Europe for treating resistant major depressive disorder
Mahase, E. | BMJ | 20 December 2019
Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
Family, N., Maillet, E. L., Williams, L. T., Krediet, E., Carhart-Harris, R. L., Williams, T. M., ... & Raz, S. | Psychopharmacology | 18 December 2019
Decreased directed functional connectivity in the psychedelic state.
Barnett, L., Muthukumaraswamy, S. D., Carhart-Harris, R. L., & Seth, A. K. | NeuroImage | 17 December 2019